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ma difuză mai frecvent e prezentă diarea (77,8% ver-
sus 2,6%, p<0,01), sindromul de malabsorbţie (11,1% 
versus 0%, p<0,01), pierderea ponderală (70,4% versus 
14,1%, p<0,01), iar în forma limitată – disfagia (66,7% 
versus 44,4%, p<0,05), pirosisul (50% versus 33,3%, 
p<0,05), constipaţia (49,7% versus 11,1%, p<0,01), 
incontinenţa anală (5,1% versus 0%, p<0,05).
Concluzii
1. Afectarea digestivă la pacienţii cu scleroder-
mie sistemică este frecventă, diversă și complexă.
2. Pacienţii cu forma difuză a bolii mai frecvent 
prezintă diaree, sindrom de malabsorbţie și pierdere 
ponderală. 
3. Pacienţii cu forma limitată a maladiei suferă 
ma frecvent de disfagie, pirosis, constipaţii și incon-
tinenţă anală. 
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Summary
Secondary osteopenia at chronic pancreatitis and ways 
of correction
The expediency of taking Vitrum Calcium 600+D400 in the 
complex treatment of patients with chronic pancreatitis ac-
companied with osteodefi ciency has been proved. Taking of 
the medication led to substantial reliable (p<0,05) improve-
ment of bone mineralization – mineral density has increased 
by (0,279±0,020) g/cm² and by (3,31±0,47)%, bone and 
mineral metabolism indexes (alkaline phosphatase, calcium 
and phosphorus) have optimized.
Keywords: chronic pancreatitis, osteodeficiency, bone 
mineral density, mineral metabolism, Vitrum Calcium 
600+D400.
Резюме
Комплексное лечение больных хроническим панкреа-
титом с сопутствующим остеодефицитом
Доказана целесообразность использования препарата 
Витрум Кальциум 600+D400 в комплексном лечении 
больных хроническим панкреатитом с сопутствую-
щим остеодефицитом, что привело к существенному 
достоверному (p<0,05) улучшению состояния минера-
лизации кости – приросту минеральной плотности на 
(0,279±0,020) г/см² и на (3,31±0,47) %, оптимизации 
показателей костно-минерального метаболизма – ще-
лочной фосфатазы, кальция, фосфора.
Ключевые слова: хронический панкреатит, остеоде-
фицит, минеральная плотность костной ткани, мине-
ральный обмен, Витрум Кальциум 600 + D400.
Introduction
The problem of osteodeficiency (OD) on the 
background of chronic pancreatitis (CP) is one of 
the pressing in modern medicine. Delayed diagnosis 
of secondary osteoporosis (OP) caused by severe 
manifestation of the basic disease often leads to 
such complications as fractures [1, 2, 7]. 
Judging by recent publications it is obvious 
that the core reason of OD formation is violations 
of micronutrient homeostasis and metabolism of 
vitamin D, malabsorption and maldigestion syn-
dromes. Thus, special attention should be payed to 
the fact that polynutrient insufficiency and tropho-
logic disorders accompanied with CP cause OD and 
both osteoporosis and osteomalacia as the result of 
vitamin D deficiency [8, 9]. In addition, CP is often ac-
companied with hypoalbuminaemia which induces 
the inferiority of protein part of the musculoskeletal 
system of the patient [5].
The threat of irreversible changes in the mus-
culoskeletal system in patients with CP determines 
the necessity to solve the question of finding a ra-
tional therapy and the development of preventive 
measures.
The main requirements for correction of OD 
with CPs are: complex treatment of the basic dis-
ease, careful selection of medications to inhibit OP 
considering the impact on its pathogenetic links 
with minimal negative effects and polypharmacy. 
15
G A S T R O E N T E R O L O G I E
One of the new perfectly balanced and economi-
cally accessible antiosteoporosis means is Vitrum 
Calcium 600+D400 by Pharmaceutical Company 
UNIPHARM, Inc., USA.
The aim of the investigation is to prove the 
expediency of using the medication Vitrum Calcium 
600+D400 in the complex treatment of patients with 
CP accompanied with concomitant osteodeficiency 
syndrome. This is a part of the complex theme “The 
role of neuroendocrine and immune interactions 
and the development of its corrective methods for 
patients with secondary osteoporosis.”
The main tasks are to prove the effectiveness 
of Vitrum Calcium 600+D400 in the therapeutic 
treatment of CP to correct bone loss and mineral 
metabolism disorders.
Materials and methods
The object of our study were 75 patients with 
CP who had regular medical check-up in outpatient 
department of Ternopil hospital №2. The age of pati-
ents was from 23 to 72; sex – 31male and 44 – female. 
CP was diagnosed on the basis of anamnesis, clinical 
strokes of the disease (pain, dyspeptic, exocrine 
insufficiency, allergic, astheno-vegetative, entero-
pancreatic and endocrine disorders syndrome), labo-
ratory data (including blood amylase, urine diastase, 
glycemic profile), the results of abdomen ultrasound 
investigation, gastroscopy [10]. The exclusion crite-
ria was the presence of other pathology that could 
cause the development of secondary OP. To judge 
upon the condition of bone mineral density (BMD) 
each patient had densitometric examination of the 
lumbar spine by Dual Energy X-Ray Absorptiometry 
(DXA) made by Lunar corp. (Madison, WI) – Lunar 
DPX-A №2589. The base of the analysis of changes 
in BMD is formed by data obtained in statistically 
sufficient population studies of groups of healthy 
people of different race, gender, age, weight and 
height [11]. The assessment of BMD according to 
the stages was conducted in accordance with WHO 
recommendations and L.Y. Rozhynska proposals 
[12]. The results were processed statistically using a 
personal computer with standard statistical package 
of application programs and evaluated by Student’s 
criteria.
The concentration of calcium, inorganic pho-
sphorus in serum and alkaline phosphatase (ALP) 
levels were determined by conventional methods [3]. 
The control group consisted of 20 healthy persons.
Patients with CP and concomitant OD were di-
vided into two groups of program correction. Group 
I (15 patients) received generally accepted in gastro-
enterology medical complex (ML) on demand, accor-
ding to the patient’s condition. It included diet №5 
by Pevsner, Omeprazole (20 mg once per day, Creon 
25000 (3 times per day with meals), Nospanum forte 
(80 mg twice per day), Motilium (10 mg 3 times per 
day before food). Group II (15 patients) received ML 
complex together with Vitrum Calcium 600+D400 
according to the following therapeutic scheme: 1 
capsule of Vitrum Calcium 600+D400 twice per day 
during or after meals during 1 month, and then 1 
capsule once a day during 2 months.
Vitrum Calcium 600+D400 (Certificate of Mi-
nistry of Health of Ukraine № UA/1721/01/01) is a 
complex of calcium supplements (in the form of 
calcium carbonate from oyster shells) 600 mg and 
vitamin D3 (cholecalciferol) 10 mcg (400 IU).
No complications and side-effects have been 
observed in our investigation. Investigated para-
meters were determined before treatment and 6 
months after its beginning.
Results and discussion
The table presents the results of effects of both 
treatment programs. It includes the data of bone and 
mineral metabolism of patients with PC.
The dynamics of data in patients with CP with concomitant 
osteodeficiency under various medical complexes
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Notes: * – probable difference regarding indices of the relevant 
research group before treatment (p <0,05). All indices of bone 
tissue are reliable regarding reference database Lunar.
Under the influence of ML patients with CP 
accompanied with OD: Group I (initial data referred 
to osteopenia of II stage) indices of bone tissue 
decreased, although the changes were not reliable 
(p>0,05). In Group II (initial data referred to osteo-
penia of the III stage), we noted the growth of BMD 
by (0,279±0,020) g/cm² and by (3,31 ± 0,47) %. Thus, 
taking Vitrum Calcium 600+D400 according to the 
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suggested scheme during the year led to significant 
reliable (p<0,05) improvement of bone mineraliza-
tion. It should be noted that the level of total cal-
cium in blood in Group I during the treatment has 
not changed and was in the normal range (index 
in the control  group   of   healthy young  people 
– (2,25±0,11) mmol/l. The level of total calcium in 
blood in Group II before treatment was slightly lower 
in relation to the control group (p<0,05), after the 
correction it increased significantly and was within 
normal limits. The level of inorganic phosphorus in 
both research groups was within the normal range 
(control group index – (1,17±0,13) mmol/l), before 
as well as after the treatment. A significant increase 
of this parameter (p< 0,05) in Group II after the cor-
rection should be noted. ALP Index as the marker 
of bone metabolism in research groups was in the 
normal range, although a significant decrease of this 
index in Group II after the treatment (p<0,05) should 
be noted. These figures proved a positive balance of 
bone remodelling in favour of osteoformation after 
the correction.
Thus, the analysis of received data proves the ef-
ficiency of the medication Vitrum Calcium 600+D400 
in the complex treatment of patients with CP for 
correction of accompanying OP, mineral metabolism 
disorders and their prevention.
Conclusions
1. Taking of Vitrum Calcium 600+D400 according 
to the suggested scheme in the complex treatment 
of patients with chronic pancreatitis with concomi-
tant osteodeficiency led to the substantial significant 
(p<0,05) improvement of bone mineralization – the 
increase of mineral density by (0,279±0,020) g/cm² 
and by (3,31±0,47) %, optimizing the figures of bone 
and mineral metabolism - alkaline phosphatase, cal-
cium and phosphorus (half a year after the beginning 
of the treatment).
2. It is reasonable to subscribe Vitrum Calcium 
600+D400 according to the following therapeutic 
scheme – 1 capsule twice a day during or after meals 
during 1 month, and then – 1 capsule once a day 
during 2 months.
In the future we’ll plan further research to 
examine the impact of Vitrum Calcium 600+D400 
in combination with antiresorptional medications 
for bone tissue of patients with CP and concomitant 
osteodeficiency.
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